AIM Breakfasts

AIM BREAKFAST – 13th October 2016

Set Menu AIM:

Total number of AIM Companies (Incl Susp): 996

Total number of AIM Companies trading: 978*
* As at 12 October 2016

Dish of the Day:

No AIM Primary Today

Off the Menu:

Gable Holdings Inc. (GAH.L) cancelled its securities pursuant to AIM Rule 1  

Set Menu ISDX Growth:

Total number of ISDX Growth Market Companies (Incl Susp): *

Total number of ISDX Growth Market Companies trading: *
* As at 12 October 2016

Dish of the Day:

Off the Menu:

What’s Cooking in the IPO Kitchen?

Biffa— The waste disposal company’s IPO is also now in doubt with the valuation coming under scrutiny according to the press

TI Fluid Systems– has decided not to proceed with its proposed initial public offering at the current time due to market conditions

Van Elle—The geotechnical contractor to the UK construction market is hoping to come to AIM later this month

Ascot Lloyd— The UK IFA is also hoping to join AIM later this month. Ascot Lloyd’s strategy is to grow through a combination of organic growth and further targeted acquisitions.


Breakfast Buffet

Cambridge Cognition Hldgs* (COG.L) 80p £16.34m

The neuroscience company has announced new contracts worth  >£0.25m to assess, through CANTAB Connect, the abuse potential of investigational drugs in a new market application for the Company. The contracts announced today will use CANTAB Connect to assess abuse potential in a new, unexplored and growing therapeutic area, which is an extension of the HAL market targeted to date. Since launching CANTAB Connect in 2014 COG has become the leader in Human Abuse Liability assessment technology generating >£3m of revenue.


Imperial Innovations Group (IVO.L) 418.75p £675m

FYJul16 results from the  technology commercialisation and investment group.  Quoted net fair value loss of £66.9 million (largely as a result of decline in Circassia share price). However  £69.9 million invested across 33 portfolio companies. The rate of investment has doubled over the last two years. Current year has started well with the £30.6m plus sale of Permasense and 5 year contract to run the I-HUB incubator at Imperial College. Portfolio company Crescendo Biologics signed collaboration and licence agreement with Takeda Pharmaceutical worth up to  $790m. NAV £455.9m.


Crimson Tide (TIDE.L) 2.82p £12.64m

The provider of mpro5 ‐ Smart Mobility as a Service, has signed its most significant long term contract with a large UK retailer. Its mpro5 service will be used to ensure store safety, cleanliness and security.  This deployment follows a successfully executed pilot. The contract value is worth over £1.7m of additional revenue over an initial term of 48 months, the largest gross revenue contract in the Company’s history. FYDec2016E revenue £1.8m and EPS of 0.11p. 0.02p dividend.


Ideagen (IDEA.L) 55.5p £100.7m

The supplier of Information Management software to highly regulated industries, has, over the past month been awarded three important contracts with new customers in key vertical markets worth a combined value of £1.2m. Two of the new contracts represent key customer wins in the aviation sector. In addition, Medway NHS Trust has selected Ideagen to provide a secure platform which will enable the Trust’s laboratories to electronically communicate with GP practices. FYAPR17E revenues £25.4m,  EPS 3.1p, Dividend 0.2p.


Versarien (VRS.L) 10.13p £11.79m

The advanced materials group, has announced the successful completion of a grant funded project focused on graphene enhanced carbon fibre composites with the National Graphene Institute (“NGI”) at The University of Manchester. Following the positive test results from the project the NGI have indicated that they wish to purchase a significant quantity of graphene from Versarien for a specific project with a major OEM. Mar 2017E revenues of £7.6m and pre-tax loss of £0.3m.


Kolar Gold (KGLD.L) 1.75p £3.38m

The India gold exploration and mine development company, has entered into a Memorandum of Understanding  to establish a Joint Venture (“JV”) to develop gold exploration and mining assets in Finland. High grade targets within licences covering an area of approximately 24km sq. Potentially cashflow generative within 12 months via bulk sampling. Upfront €300k half cash half shares. €1.35m earn in will get Kolar 50% of JV.


Sula Iron & Gold (SULA.L) 0.11p £0.95m

The multi-commodity exploration company focused on Sierra Leon  has conditionally raised $400k at 0.1p. The net proceeds of the Subscription will be used by Sula to advance its Ferensola Gold Project in northern Sierra Leone and for general working capital purposes. The subscription has been taken up by Madini Occidental Ltd, a private company incorporated in the Republic of Seychelles, which is currently owned by Madini Minerals (“Madini”) and Ian Schofield. Madini is bringing a CEO and non-exec to the Board.


Iofina (IOF.L) 12.25p £15.63m

The specialists in the exploration and production of iodine and iodine specialty chemical derivatives, has updated the market today on the Company’s Q3 iodine production. The Group produced 125.1 metric tonnes of crystalline iodine in Q3 2016, and has produced 380.7 MT year to date from five IOsorb® plants in Oklahoma. The Group remains on track to meet  production targets of 250-270 MT of crystalline iodine in H2 2016. As recently communicated, Iofina and its partners have completed improvement projects at three plants during the Period.


Vianet Group (VNET.L) 94.5p £26.43m

The provider of real time monitoring systems, data management services and business intelligence for the leisure and vending sectors has provided a HYSep16 trading update. Trading is ahead of the comparative period and in line with expectations. Expecting to maintain 1.7p interim dividend. FYMar17E revenue of £14.9m and EPS of 7p. FY divs of 5.7p. 6% yield. 13.6x PE.


Goldstone Resources (GRL.L) 2.25p £2.3m

The West and Central Africa focused gold exploration company quoted on AIM, has been made aware that a former director and employee of the Company has made a claim in The Labour Court of South Africa for certain sums relating to the termination of his employment.  The sum being sought would represent a significant proportion of the Company’s current cash resources. The Company is considering the claim with its legal advisers and intends to robustly defend the claim and will make further announcements as and when appropriate.


Head Chef:

Derren Nathan
0203 764 2344

*A corporate client of Hybridan LLP


This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific entity and is not a personal recommendation to anyone. Recipients should make their own investment decisions based upon their own financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.

The information contained in this document is based on materials and sources that are believed to be reliable; however, they have not been independently verified and are not guaranteed as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information in this document nor should it be relied upon as such.

Any and all opinions expressed are current opinions as of the date appearing on this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.

This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, does not constitute “independent investment research” for the purposes of the Financial Conduct Authority rules. The individuals who prepared this document may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, directors, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.

In the UK, this document is directed at and is for distribution only to persons who (i) fall within Article 19(5) (persons who have professional experience in matters relating to investments) or Article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) or (ii) are Professional Clients or Eligible Counterparties (as those terms are defined in the rules of the Financial Conduct Authority) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as “relevant persons”). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by persons who would be classified as Retail Clients (as defined by the rules of the Financial Conduct Authority).

Neither this document nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of UK or US securities law, or the law of any such other jurisdictions.

Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, directors, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.

Neither the whole nor any part of this document may be duplicated in any form or by any means. Neither should this document, or any part thereof, be redistributed or disclosed to anyone without the prior consent of Hybridan LLP.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX. If you would like to unsubscribe, please email with “unsubscribe me”.